Nowadays, new molecular subtypes have been widely clinically utilized to predict the prognosis and therapy outcomes of the glioma patients, such as IDH (isocitrate dehydrogenase) mutation and 1p/19q codeletion on chromosomal and 6-O-methylguanine-DNA methyltransferase (MGMT) promoter methylation (Lim et al., 2018). This evidence concerns the gene IDH1 and central nervous system cancer.